Citius Oncology, Inc. (NASDAQ:CTOR - Get Free Report) dropped 2.8% on Wednesday . The company traded as low as $0.86 and last traded at $0.89. Approximately 71,189 shares changed hands during mid-day trading, a decline of 94% from the average daily volume of 1,127,937 shares. The stock had previously closed at $0.92.
Citius Oncology Price Performance
The company has a debt-to-equity ratio of 0.08, a current ratio of 0.34 and a quick ratio of 0.08. The stock's fifty day simple moving average is $0.74 and its two-hundred day simple moving average is $1.00.
Citius Oncology (NASDAQ:CTOR - Get Free Report) last issued its quarterly earnings results on Wednesday, May 14th. The company reported ($0.11) earnings per share for the quarter, missing analysts' consensus estimates of ($0.09) by ($0.02).
Institutional Trading of Citius Oncology
A hedge fund recently bought a new stake in Citius Oncology stock. Citadel Advisors LLC acquired a new stake in shares of Citius Oncology, Inc. (NASDAQ:CTOR - Free Report) in the fourth quarter, according to its most recent disclosure with the Securities & Exchange Commission. The institutional investor acquired 22,699 shares of the company's stock, valued at approximately $26,000. 70.52% of the stock is owned by institutional investors.
About Citius Oncology
(
Get Free Report)
Citius Oncology, Inc is a pharmaceutical company, which engages in developing and commercializing targeted oncology therapies. Its lead product candidate is LYMPHIR, an engineered IL-2 diphtheria toxin fusion protein, for the treatment of patients with persistent or recurrent CTCL, a rare form of non-Hodgkin lymphoma.
Further Reading
Before you consider Citius Oncology, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Citius Oncology wasn't on the list.
While Citius Oncology currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
MarketBeat's analysts have just released their top five short plays for June 2025. Learn which stocks have the most short interest and how to trade them. Enter your email address to see which companies made the list.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
